Antibody response to insulin aspart and human insulin in children and adolescents with newly diagnosed type 1 diabetes

被引：0
|
作者：
Holmberg, Hanna
Mersebach, Henriette
Hanzel, Karin Kanc
Ludvigsson, Johnny
机构：
来源：
DIABETES | 2007年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A476 / A476
页数：1
相关论文
共 50 条
  • [1] Treatment with insulin aspart versus human insulin in children and adolescents with newly diagnosed type 1 diabetes
    Ludvigsson, J.
    Mersebach, H.
    Hanzel, K. Kanc
    Holmberg, H.
    [J]. DIABETOLOGIA, 2007, 50 : S380 - S380
  • [2] Antibody response to insulin in children and adolescents with newly diagnosed Type 1 diabetes
    Holmberg, H.
    Mersebach, H.
    Kanc, K.
    Ludvigsson, J.
    [J]. DIABETIC MEDICINE, 2008, 25 (07) : 792 - 797
  • [3] INSULIN ANTIBODY-RESPONSE TO HUMAN INSULIN ADMINISTRATION IN CHILDREN WITH NEWLY DIAGNOSED INSULIN-DEPENDENT DIABETES (IDD)
    DANEMAN, D
    SOCHETT, E
    FISHMAN, L
    [J]. CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1986, 9 (03): : A28 - A28
  • [4] Pharmacokinetics of a rapid-acting human insulin analogue, insulin aspart, in children and adolescents with type 1 diabetes
    Mortensen, H
    Olsen, B
    Li'ndholm, A
    [J]. DIABETES, 1999, 48 : A358 - A358
  • [5] Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
    Thalange, Nandu
    Deeb, Larry
    Iotova, Violeta
    Kawamura, Tomoyuki
    Klingensmith, Georgeanna
    Philotheou, Areti
    Silverstein, Janet
    Tumini, Stefano
    Ocampo Francisco, Ann-Marie
    Kinduryte, Ona
    Danne, Thomas
    [J]. PEDIATRIC DIABETES, 2015, 16 (03) : 164 - 176
  • [6] Biphasic insulin aspart vs. human insulin in adolescents with type 1 diabetes on multiple daily insulin injections
    Mortensen, H
    Kocova, M
    Teng, LY
    Keiding, J
    Bruckner, I
    Philotheou, A
    [J]. PEDIATRIC DIABETES, 2006, 7 (01) : 4 - 10
  • [7] Endogenous insulin retention by oral insulin in newly diagnosed antibody positive type-1 diabetes
    Krischer, J
    Ten, S
    Marker, J
    Coutant, R
    Kukreja, A
    Zhang, CH
    Zhong, S
    Raskin, P
    Bode, B
    Vargas, A
    Rogers, D
    Schatz, D
    Deeb, L
    Marks, J
    Schwartz, S
    Malone, J
    Rapaport, R
    Zeidler, A
    MacLaren, N
    [J]. DIABETES, 2001, 50 : A44 - A44
  • [8] Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes
    Biester, Torben
    Danne, Thomas
    Blaesig, Sarah
    Remus, Kerstin
    Aschemeier, Baerbel
    Kordonouri, Olga
    Bardtrum, Lars
    Haahr, Hanne
    [J]. PEDIATRIC DIABETES, 2016, 17 (08) : 642 - 649
  • [9] Efficacy and safety of fast-acting insulin aspart versus insulin aspart in children and adolescents with type 1 diabetes from Japan
    Kawamura, Tomoyuki
    Kikuchi, Toru
    Horio, Hiroshi
    Rathor, Naveen
    Ekelund, Magnus
    [J]. ENDOCRINE JOURNAL, 2021, 68 (04) : 409 - 420
  • [10] Insulin aspart versus insulin lispro via continuous subcutaneous insulin infusion (CSII) in children and adolescents with type 1 diabetes
    Weinzimer, Stuart
    Laffel, Lori
    Ternand, Christine
    Howard, Campbell
    Chang, C. T.
    Becker, Dorothy
    [J]. DIABETES, 2007, 56 : A478 - A478
12345